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Abstract
Background: Antidepressant prescribing continues to increase, with 5-16% of adults receiving antidepressants
annually. Total prescribing growth is due in part to increased long-term use, greater selective serotonin re-uptake
inhibitor (SSRI) use and the use of higher SSRI doses. Evidence does not support routine use of higher SSRI doses
for depression treatment, and factors influencing the use of such doses are not well known. The aim of this study
was to explore factors influencing GPs’ use of antidepressants and their doses to treat depression.
Methods: Semi-structured interviews with a purposive sample of 28 practising GPs; sampled by antidepressant
prescribing volume, practice size and deprivation level. A topic guide drawing on past literature was used with
enough flexibility to allow additional themes to emerge. Interviews were audio-recorded and transcribed verbatim.
Framework analysis was employed. Constant comparison and disconfirmation were carried out across transcripts,
with data collection being interspersed with analysis by three researchers. The thematic framework was then
systematically applied to the data and conceptualised into an overarching explanatory model.
Results: Depression treatment involved ethical and professional imperatives of ‘doing the right thing’ for individuals
by striving to achieve the ‘right care fit’. This involved medicalised and non-medicalised patient-centred approaches.
Factors influencing antidepressant prescribing and doses varied over time from first presentation, to antidepressant
initiation and longer-term treatment. When faced with distressed patients showing symptoms of moderate to
severe depression GPs were confident prescribing SSRIs which they considered as safe and effective medicines, and
ethically and professionally appropriate.
Many GPs were unaware that higher doses lacked greater efficacy and onset of action occurred within 1-2 weeks,
preferring to wait 8-12 weeks before increasing or switching. Ongoing pressures to maintain prescribing (e.g. fear of
depression recurrence), few perceived continuation problems (e.g. lack of safety concerns) and lack of proactive
medication review (e.g. patients only present in crisis), all combine to further drive antidepressant prescribing
growth over time.
Conclusions: GPs strive to ‘do the right thing’ to help people. Antidepressants are only a single facet of depression
treatment. However, increased awareness of drug limitations and regular proactive reviews may help optimise care.
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Background
Antidepressant prescribing has increased substantially
across Western societies over the last 40 years [1–3],
attracting much discussion, debate, concern and contro-
versy [1, 4, 5]. The issues are wide and varied: whether
antidepressants are overprescribed or not [4, 5]; whether
antidepressants are effective or ineffective in treating
depression [6]; Westernised societies’ expected right to
happiness and consequential medicalisation of unhappiness
[7, 8]; the direct/indirect role which the pharmaceutical
industry may have in influencing the definition of depres-
sive disorder [9, 10]; promoting simple marketing models
of depressive illness [11]; ‘ghostwriting’ antidepressant stud-
ies [9, 10]; and more controversially, reporting bias, missing
data [12], and antidepressant associated self-harm [13].
Despite these debates and controversies, depression
remains a common, recurrent, debilitating and potentially
fatal condition with antidepressants being only one of the
many components of depression treatment which have
been shown to be effective [14–17].
Although prescribing continues to increase, there has
been no corresponding increase in depression incidence
or prevalence [18, 19]. Most antidepressants are pre-
scribed by general practitioners (GPs) with the majority
(60-85%) of adults receiving them for the treatment of
depression [20–22] and a minority receiving them for
other conditions [23], with an estimated 5-16% of adults
receiving antidepressants in Europe and USA annually
[24, 25]. Factors that have contributed to prescribing
growth include: the introduction of tricyclic antidepres-
sants (TCAs) in the late 1960s [1], then the addition of
selective serotonin re-uptake inhibitors (SSRIs) in the
1980s [26]; increased long-term prescribing in the 1990s
and 2000s [19]; lack of regular review [27]; and more re-
cently the use of higher doses [21, 28, 29].
SSRIs are of particular interest as they account for the
majority of antidepressant prescriptions, dominating anti-
depressant volumes across Western Societies [24, 25], and
are routinely prescribed at higher doses than previ-
ously reported in the literature in the UK and New
Zealand [21, 29]. In one study, higher than standard
SSRI doses were associated with the practice which
the patient attended; long-term use of SSRIs; and co-
prescribing of SSRI with long-term benzodiazepines
and/or z-hypnotics (B&Zs) [22]. However, current evi-
dence does not support the routine use of higher li-
censed doses as they lack greater efficacy [17, 30, 31].
Higher doses are also associated with more adverse
effects including anxiety, agitation and insomnia [30]
which may lead to co-prescribing of sedating drugs
such as B&Zs, antipsychotics and other antidepres-
sants such as trazodone. Such combinations of high
dose SSRI and sedating antidepressant use may also
influence the large variations in antidepressant
volumes prescribed between practices [32]. There is a




The aim of this study was to explore factors influencing
GPs’ use of antidepressants and their doses to treat
depression.
Design and setting
Quantitative methods can be limited in providing depth of
clarity on this issue, therefore qualitative methods were
used to enable an in-depth understanding of GPs’ perspec-
tives and rationale for prescribing. Focus groups were con-
sidered inappropriate as it was expected that predominant
voices may drown out more moderate voices, and imprac-
tical for busy GPs to attend within normal working hours.
Therefore we captured in-depth GP perspectives on their
practical experience and opinions of what influences their
antidepressant prescribing through one-to-one, face-to-
face, interviews conducted in each GP’s office.
Sampling and recruitment
We recruited 28 GPs working in general practices across
the National Health Service Greater Glasgow and Clyde
(NHSGG&C) region in Scotland. NHSGG&C provides
taxpayer funded healthcare services for a diverse popula-
tion of 1.2 million people across a varied urban region
containing 260 general practices.
In order to achieve information-rich cases and di-
verse perspectives, a purposive sample was sought by
allocating all general practices in NHSGG&C to a
sampling frame using practice characteristics: volume
of antidepressants prescribed; number of GPs; and
practice deprivation score. We aimed to recruit 30
GPs from across NHSGG&C with an equal number
of male and female GPs, and a proportion of GPs
partners working in the same practice (7 practices).
Antidepressant prescribing data for the 260 practices
was obtained from the Prescribing and Information
System for Scotland for year to March 2014, as previ-
ously described [22]. The 260 practices were first ranked
from lowest to highest antidepressant prescribers, and
then categorised as low, medium and high prescribers
based on the number of defined daily doses (DDDs)/
1000 patients. These were then subcategorised as small
(single handed GP), medium (2-3 GPs) and large (≥4
GPs) by the number of GPs contracted to individual
practices, as recorded in April 2014 [33]. Finally,
practices were ranked by Scottish Index of Multiple
Deprivation rank derived from each practice’s postcode
[34], and categorised as being in areas of low, medium
and high deprivation.
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Between August 2014 and December 2015, GPs
matching the sampling frame were initially contacted
by letter and followed up by telephone within 2 weeks
by administrative staff. In total 188 GPs were written
to, in groups of 30 to 40, during the study period.
GPs were informed about the aims of the study, that
study findings would be used to support appropriate
antidepressant use within NHSGG&C, and that previ-
ous NHSGG&C work had identified the routine use
of higher SSRI doses [21, 22]. Potential participants
showing interest were then contacted by CFJ to
arrange interviews at their offices’. Prior to interviews
starting, CFJ discussed the study and sought
participant’s consent for inclusion in the study. GPs
were not incentivised to participate in any way. A
total of 28 GPs participated, 14 male and 14 female,
see Table 1.
Data collection
One-to-one, face-to-face, semi-structured interviews
were carried out by one researcher, a prescribing sup-
port pharmacist (CFJ), at the GP’s office. Interviews
lasted between 15 and 55 min with most lasting
approximately 30 min. Although an initial topic guide
was developed using previous literature, it was flexible
enough to allow additional topics to emerge (see
Additional file 1: Topic guide for first interview (v6)
and final version of topic guide (v14)). Interviewees
were also asked for their perspectives on factors asso-
ciated with higher SSRI dose use for depression treat-
ment as previously identified [22]. Early interviews
and subsequent interviews informed the refinement of
subsequent topic guides and the inclusion of emer-
gent themes expressed as GPs’ views and experiences
at interview. Interviews were audio-recorded and
transcribed verbatim.
Analysis
Data analysis was inductive and continuous, and
began from the start of data collection. Constant-
comparative technique was used [35] while adopting
Framework analysis [36] as the broad structure for
the analytical procedure. Familiarisation with, and
constant-comparison between transcripts permitted
additional important themes to emerge. Transcripts
were initially read and emerging themes and patterns
discussed by three authors (CFJ, BW and MM) to
identify a thematic framework. Constant-comparison
and disconfirmation were then carried out repeatedly
and systematically (by CFJ) between transcripts to en-
hance and confirm the thematic framework. Data col-
lection was interspersed with analysis, with findings
informing subsequent interviews, allowing inter-
viewees to explain and/or expand on key themes. As
CFJ was aware that being a prescribing support
pharmacist may influence GPs’ responses, interviewees
were asked if this could have affected their responses.
The thematic framework was then systematically ap-
plied to the data which were indexed and summarised
in charts, by CFJ. Broad themes and patterns (map-
ping), both within and across interviews were identi-
fied. NVivo 11 was used to store and organise data.
From this process, an understanding of the factors
influencing GPs decision-making regarding the use of
antidepressants and their doses emerged, and were
conceptualised into an overarching explanatory model of
factors influencing prescribing.
Ethical approval
The study was approved by the Ethics Committee of the
School of Health Sciences, University of Stirling 21st
April 2014.
Table 1 Individual GP and practice characteristics
Individual GP Characteristics (n = 28)
Female (%) 14 (50)
Median age (range) 43 (33 to 60)
Years since qualified as doctor, median (range) 19 (10 to 37)
Years as a GP median (range) 12 (2 to 33)
Number of GPs with psychiatry training as part of GP training rotation (%) 19 (68)
Number of GPs with extra psychiatric training/experience as locum or psychiatry trainee (%) 4 (14)
Individual practice characteristics (n = 20)
Antidepressant volumes in DDD/1000 patients, n (GPs) Low = 9 (10) Medium = 4 (6) High = 7 (12)
Number of GP partners, n (GPs) Small (single handed) = 1 (1) Medium (2-3 GPs) = 10 (13) Large (≥4 GPs) = 9 (14)
Deprivation, n (GPs) Low = 6 (6) Medium = 5 (7) High = 9 (15)
Training practice, n (GPs) Yes = 10 (16) No = 10 (12)
DDD defined daily doses. DDDs are units of measurement defined by the World Health Organization as ‘the assumed average maintenance dose per day for a
drug used for its main indication in adults’. DDDs do not necessarily reflect the recommended or prescribed daily dose but allow a convenient method to
compare prescribing volumes between organisations [59]
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Results
Analysis revealed that depression treatment involved two
key overarching concepts of ‘doing the right thing’ and
achieving the ‘right care fit’ for individuals. This involved
medicalised and non-medicalised patient-centred ap-
proaches with antidepressants only being a single facet of
treatment. However, factors influencing antidepressant
prescribing and prescribed doses varied over time from first
presentation and the beginning of treatment, to antidepres-
sant initiation and longer-term treatment (Fig. 1). Seven
interwoven factors influenced antidepressant prescribing.
Five of these factors can be described as strongly in-
fluential: 1) Depression diagnosis and management; 2)
Patients’ expectations and characteristics; 3) GP’s ex-
perience and relationships; 4) Antidepressant use:
safety, risk management and effectiveness; 5) Review
frequency. Two were moderately influential: 6) Local
prescribing resources and 7) Mental health services.
As outlined below with illustrative quotes, also see
Additional file 2: Supplementary quotes.
The magnitude of the influence exerted by these fac-
tors varied with time. For example, review frequency
was high and highly influential at the beginning of
treatment in supporting and increasing appropriate anti-
depressant use for more severe illness, whereas in the
intermediate period following the first few months of
antidepressant treatment, review frequency decreased,
thereby reducing the potential for appropriate continu-
ation or discontinuation. In the longer-term, reviews
became more infrequent and coupled with some patients
presenting in crisis further increased cumulative
prescribing (Fig. 1).
When faced with patients showing symptoms of mod-
erate to severe depression, GPs were confident prescrib-
ing SSRIs, which they considered safe and effective
medicines. Prescribing was seen ethically and profession-
ally as ‘doing the right thing’ for the patient in the face
of distress. However, many were unaware higher doses
lacked greater efficacy and onset of action occurred
within 1-2 weeks, preferring to wait 8-12 weeks before
increasing or switching. The ongoing pressures to main-
tain prescribing (e.g. patient wishes, fear of depression
recurrence), few perceived continuation problems (e.g.
lack of safety concerns) and the lack of proactive
medication reviews (e.g. patients only present in crisis)
contributed to further antidepressant prescribing growth
over time (Fig. 1).
Depression diagnosis and management
Diagnosing depression
Across the sampling frame diagnosing depression was
rarely seen as a simple task or process. This was due to a
Fig. 1 Factors increasing and decreasing antidepressant prescribing for depression treatment. Factors strongly influencing antidepressant
prescribing bold and moderately influential factors in italics and underlined. ADM: antidepressant. DNA: do not attend. PST: Prescribing Support
Teams. SSRI: selective serotonin re-uptake inhibitor
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variety of issues and complex interactions involving: normal
life events; relationship problems; social and environmental
issues; patients’ expectations of happiness; duration of
symptoms; mixed anxiety and depressive symptoms; co-
morbidities; and the risk of medicalising normal and “ap-
propriate misery” (D21,18p3) due to life events. However,
time well spent in this initial presentation period – regu-
larly reviewing patients – was seen as an important part of
the biopsychosocial assessment. Some practitioners rou-
tinely used depression rating scales to quantify depression
severity or as a tool to support discussions with patients,
whereas others found rating scales hampered assessment,
or were not used as they lacked a social domain. Patient in-
formation was used to ascertain and balance how well
signs, symptoms and subjective assessment fitted with stan-
dardised concepts of clinical depression and severity to
achieve the best treatment ‘fit’ (Fig. 2).
…the bottom line for GPs is that we want to help, we
want to offer something that we think will help. D12,8
You also want to look at the person as a whole and
find out where they are in their life. You have to assess
the actual severity of the situation before determining
what kind of treatment would be appropriate for
them. Then, we would go down the route of discussing
what sort of therapies we could offer them. D25,6
In general, GPs rarely prescribed antidepressants at
the first presentation, unless patients had a recurrent
depressive episode where antidepressants were previ-
ously effective, as a large proportion of patients pre-
sented in crisis and were experiencing an acute
reaction to life events or stressors. GPs in our study
viewed it as more important to listen to patients and
discuss issues in the first instance, especially for
mild to moderate forms of depression where patients
needed someone to talk to, not prescribe. Allowing a
period of ‘watch and wait’ where depressive symp-
toms would remit.
…for a lot of people with a mild to moderate
depressive illness, is to say, “you might not
need anything here. You might just need,
someone to talk to you about it and some
support and things might improve on their
own.” D12,96
Fig. 2 Balancing treatment and management options. Factors strongly influencing antidepressant prescribing bold and moderately influential factors
are in italics and underlined
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Although for some patients, there was an expectation
about receiving something.
They think they’re coming here [pause] for me to do
something for them [empathetically said]. And that,
they almost feel as if there needs to be a physical
display of that, like the prescription or whatever.
D2,14
For more severe cases, and for patients that GPs knew
well, they would consider prescribing at the first presenta-
tion if symptoms were sufficiently severe to warrant an
antidepressant. However, this was not routine practice.
Referral to specialist Community Mental Health Teams
(CMHTs) was also considered for people with more severe
symptoms.
More than drugs
Treatment involved more than drugs. As already identi-
fied, GPs considered listening, talking and allowing
patients time for spontaneous remission as an important
core part of appropriate care, treatment and manage-
ment. For all severities of depression, and where patients
preferred not to take antidepressants for moderate to
more severe depression due to stigma or personal
choice, GP’s embraced, supported and used multiple
options to manage and treat signs and symptoms in line
with the patient’s preferences. This included a varied
array of medical and non-medicalised approaches: creat-
ing space for patients by using sickness certification;
exercise and exercise referrals to local council gyms;
counselling; signposting to information sources e.g.
Links-workers to address money worries; bibliotherapy
in libraries; online cognitive behavioural therapy e.g.
Moodgym; talking therapies via NHS and non-NHS
providers in combination with or without antidepres-
sants. A multifactorial interwoven approach was thus
created in achieving the ‘right care fit’ and ‘doing the
right thing’, with drug treatment being only one of many
therapeutic approaches.
I explain to them that, “You have to look at this
[responding to an antidepressant] in conjunction with
other things.” So, it’s always going to be a
multifactorial approach. It’s never going to be just one
thing [an antidepressant]. D28,28.
Patients’ expectations and characteristics
Data indicated that GPs’ prescribing was not overtly
influenced by patients’ expectations of receiving an anti-
depressant. The need for a clear benefit to the patient was
still the main influence, assessed on the basis of knowing
the patient’s history, comorbidities and social context.
However, it was acknowledged that time pressures could
play a role, as it was difficult to discuss and encourage the
use of non-antidepressant alternatives if clinics were
running late.
I think most of my colleagues here wouldn’t prescribe
unless they felt somebody was going to get benefit from
them [antidepressants]. We all kind of have roughly
the same sense of what’s bad and what’s good. D4,24
Many GPs felt that some patients were looking for ‘a
quick fix’, and that this was rooted in wider societal
expectations that problems could and should be solved
medically. However, it was usually those with milder
symptoms that had greater expectations of ‘a quick fix’.
As they presented in crisis there was an expectation to
do something to solve the problem; a physical display
with a prescription, which was sometimes driven by fam-
ily members more than patients. For some the ‘quick fix’
was short-term antidepressant use, which stopped within
a couple of months of starting, while others did not
expect ‘a quick fix’ and wanted to avoid antidepressants
altogether.
I think there’s an expectation generally, that if there is
a problem perhaps you know there is a pill for it. I
think that is an expectation that’s held by a lot of
people. Other people are very resistant to the idea of
taking antidepressants. D18,6
GP experience and relationships
Experiential learning significantly influenced how GPs
prescribed antidepressants. This cumulative knowledge
was gained through a mixture of formal training, such as
general practice training schemes and acute psychiatric
experience, and informal reflective practice - seeing
improvements in one patient and repeating the same
intervention with others. However, with time and greater
experience prescribers formulated their own ideas about
depression management, becoming more “idiosyncratic”
to achieve the ‘best care fit’ such as using mirtazapine
rather than fluoxetine, where insomnia was a significant
issue, or sertraline instead of citalopram for patients
with cardiac disease.
I think initially absolutely with guidelines and I guess,
as I alluded to before, the more experienced I’ve got,
the more idiosyncratic I’ve got. It tends to be how a
patient’s presenting, so it might be side-effects or likely
side-effects or beneficial side-effects that may guide me
on where I would go [with treatment]. D24,20
National and local guidelines were considered by GPs
to weakly influence antidepressant prescribing, with
some specialist resources being helpful in specific
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situations e.g. switching drugs. However, local prescrib-
ing resources, namely the formulary and prescribing
support teams, did influence drug choices and cost ef-
fective prescribing decisions.
We’ve got our in-house pharmacist, and it’s
fantastic, ‘cause we sit down and talk about
these things... For example, with venlafaxine slow
release people, we’ve changed all of them [to
lower cost ordinary release], and we resisted
pressure from secondary care and patients as
well. So that’s definitely a positive influence. Because
we’re not pharmacists, and we don’t know nearly as
much about pharmacology as pharmacists do.
D26,129
Most GPs indicated they prescribed within formulary
guidance whereas psychiatrists and other specialists
tended to prescribe third or fourth line agents which
were outwith formulary guidance. This sometimes
caused friction, especially with children and adolescents
where the evidence is weaker; there were potentially
greater safety concerns and risks; and shared care struc-
tures were lacking or not considered robust enough,
thus providing a ‘poor care fit’ and raising potential
medico-legal issues.
The other issue is prescribing antidepressants in
young people. We won’t prescribe antidepressants
that are unlicensed in young people. We won’t
prescribe them in people under the age of 18 because
there is no shared-care protocol. Unfortunately,
without the support of shared-care protocol we
don’t feel really we have the specialist knowledge
to be prescribing it much for [children and
adolescents]. D25,29 We’ve been asked to prescribe
sertraline and fluoxetine, I think, in people around
about age 15. Both of which we’ve refused. We’ve
refused all of them. The issue then is that they
feel that once they’ve initiated it we should take
over the prescription. But because there’s no
shared-care protocol it still leaves us fairly vulnerable.
So, we have still decided as a partnership that we
won’t be involved in that…D25,31
However, these frictions were partly overcome where
there was good communication, supportive structures
and good relationships.
Pharmaceutical companies were considered not to influ-
ence prescribing as GPs avoided seeing company representa-
tives for a variety of reasons e.g. anger about ‘me-too’ drugs,
promotion of active isomers of cheaper older drugs sold at a
premium price. However, GPs acknowledged that compan-
ies had subtle influences on depression management.
Well... escitalopram really pissed me off, I hate that
sort of carry on, it was like loratadine and
desloratadine, I just hate that! I mean ‘me-too’ drugs
that happen to appear just as patents are running out
and are another way of creaming money out of the
unsuspecting public,… D21,70
…there was the Defeat Depression campaign and that
was the Royal College. But the Royal College and GPs
really got into tow I think with pharma in a big way,
and I think actually that was probably fairly
influential but,… pharma were probably being very
very clever there, and more subtle than usual. I would
say…people get quite well develop antibodies to
pharma now. So they actually probably have to work
harder to convince me… But they are more subtle, and
they have subtle links. D18,23
In general the media was considered not to influence
prescribing, but some GPs were aware of previous media
articles regarding fluoxetine and adolescent suicide,
which had changed prescribing habits. The media was
thought to influence patients’ attitudes and expectations
regarding depression treatment, although this was often
presented in a confused ambiguous manner.
I think that the media give quite a muddled view on
things. They all seem to be reporting the celebrities
who are getting treatment or counselling for this, that
and the other. And, then, on the other hand, they bash
GPs for overprescribing antidepressants like
sweeties.D3,20
Antidepressant use: safety, risk management and
effectiveness
Drug choice
Across the sampling frame prescribing was influenced
by GP’s prior clinical experience, severity of patient’s
depressive symptoms and needs, along with age and
comorbidities. Treatment options were agreed through
GP-patient discussions.
You aim to certainly do it [prescribe] in partnership
with the patient. At the end of the day, if you don’t do
it in partnership with them and you prescribed it, then
they won’t take it anyway, so you do it in partnership
with the patient. …based on advice, guidelines. I think
there is an element of doing what you believe is the
right thing from your own experience. D8,22
SSRIs were seen as being effective, well tolerated
and a safe choice, especially when compared to TCAs.
Consideration was also given to the slight differences
between SSRIs with fluoxetine seen by some as more
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stimulating and appropriate for depression, whereas
sertraline and citalopram were considered more ap-
propriate for mixed depression anxiety symptoms and
better tolerated. The Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) safety warning re-
garding citalopram and escitalopram causing dose
dependent QT interval prolongation, which is associ-
ated with ventricular tachycardia and sudden cardiac
death [37], had influenced prescribers who were now
using less citalopram and more sertraline.
They’re safer. So, no one in their right mind now is
going to give an MAOI if you’re a GP. There’s no good
reason to start a tricyclic rather than an SSRI unless
you’d been through a few of them [antidepressants]
already. You know, there’s far less risk from a GP’s
point of view in terms of overdosing, in terms of side
effects from the medication. D22,33
Mirtazapine’s side effects were considered beneficial
for some patients, with weight gain being positive for
underweight patients while the sedative effects alleviated
insomnia and anxiety symptoms for some. Low dose
mirtazapine was being used in preference to more trad-
itional low dose trazodone or as a safer non-addictive al-
ternative to avoid B&Zs.
…well I know that it’s a funny drug [mirtazapine],
because it’s supposed to be only sedating at low dose,
because it has the antihistamine effect. We use it a lot
at 15mg just for the sedating effects, as a non-
addictive sleeping pill, really. D26,39
Opinion was split when using mirtazapine to treat de-
pression - some quickly increased to therapeutic doses
while others maintained people on 15 mg subtherapeutic
doses. In part this may have been influenced by CMHTs
and Addictions Teams use of low dose mirtazapine as a
single agent or in combination with other antidepres-
sants. A small minority of GPs acknowledged that they
rarely added another antidepressant to augment current
treatment, e.g. adding mirtazapine to an SSRI, and
considered their practice to be influenced by CMHTs as
only a minority of these GPs had extensive psychiatric
training. Others, however, questioned the appropriate-
ness of combining antidepressants without specialist
input and considered it as the specialist’s domain, as
with other psychotropics e.g. antipsychotic augmentation
with quetiapine. Although, most were comfortable initi-
ating low dose amitriptyline for neuropathic pain for pa-
tients already receiving an antidepressant for depression.
Well that’s one of the places I have been influenced by
secondary care. Because a lot of the psychiatrists say,
we’re going to add this to augment the effect of this. It’s
usually mirtazapine and citalopram together. And I
actually do think that works, I’m not quite sure the
biochemistry behind that. But... erm, I now do that
sometimes myself. It’s often for the poor sleepers.
D26,65
SSRI efficacy: time to effect and dose response
All GPs reported that they prescribed standard therapeutic
SSRI doses: 20 mg daily for citalopram, fluoxetine and
paroxetine, or 50 mg daily for sertraline. Half considered
that SSRIs were effective within 2 to 4 weeks, with some
indicating that some patients respond well within the first
2 weeks of treatment. The remaining half considered effi-
cacy was achieved within 6 to 8 weeks. When SSRIs taken
at therapeutic doses were ineffective or partially effective,
a large proportion of GPs would wait 8 to 12 weeks before
increasing the dose or changing antidepressants. Most of
these prescribers were female and had completed GP
psychiatric or extra psychiatry training but did not differ
in other characteristics to GPs that increased or changed
sooner. In part, persevering with one antidepressant for a
longer period may have been due to concerns about giving
people an adequate trial and fears of running out of
pharmacological treatment options.
Keep them on... probably quite some time, 2 or 3
months, and if they weren’t responding, then change.
D17, 50
From experience, a minority of GPs thought that
standard SSRI doses provided maximum efficacy, with
higher doses lacking greater benefits, so rarely increased
or ‘pushed doses’ up. In contrast the majority considered
higher SSRI doses were more efficacious with sertraline
being routinely increased. There were no differences in
characteristics between the two groups, with both ac-
knowledging that psychiatrists routinely ‘pushed the
dose’ of SSRIs. However when discussed as part of the
MHRA advice restricting citalopram to lower doses,
most observed that a few patients’ depressive symptoms
worsened while most remained well controlled on lower
doses.
As we know the response to higher doses doesn’t grow,
you know, parallel to the increasing dose. So, if we get
a good response to the first dose... doubling the dose to,
a higher dose doesn’t always make a big difference.
That’s our clinical experience. D6,44
Some prescribers acknowledged being drawn into
responding to a patient’s distress by ‘doing something’
although they were aware the intervention may have
limited or negligible benefits. Some considered this to be
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less than an ideal care ‘fit’ even though it provided pa-
tients with hope, demonstrated that patients had been
listened to, and that all options were being tried.
…when you’ve got a patient, a desperate patient in
front of you wanting something to be done, it’s the
temptation is to crank up the dose. Again, one of my
colleagues will go up to much higher doses of fluoxetine
than, than perhaps the rest of us would. D3,60
SSRI efficacy: use of higher SSRI doses for depression
treatment
GPs’ opinions were sought regarding previous observa-
tions that higher SSRI doses were routinely being pre-
scribed [21, 28, 29] and that higher than standard SSRI
doses for the treatment of depression were associated with
the practice the patient attended, long-term use (receiving
the same antidepressant for ≥2 years), and co-prescribing
of long-term (≥8 weeks) B&Zs [22].
GPs considered that practice factors associated with
higher SSRI doses may be due to more aggressive pre-
scribers ‘pushing the dose’, but was in part due to pre-
scriber’s experience, what worked with previous patients
and/or if GPs had psychiatry training. Although GPs admit-
ted to being more comfortable prescribing antidepressants
and patients were more comfortable taking antidepressants,
most practitioners considered that their prescribing was
similar to their colleagues. Only two GPs considered that
they prescribed more, one due to being female and seeing
more female patients and the other because he prescribed
lots of everything.
A few GPs highlighted differences in management styles
between them and their colleagues relating to: frequency
of review and follow up, use of alternatives, and again that
a minority were happier prescribing antidepressant combi-
nations for depression, whereas the majority were not.
I think there’s two of us in the practice seeing more
people who have got psychological problems. I would
then however suspect that others might prescribe more
antidepressants per head if you know what I mean.
Whereas I would be more interested in trying
alternatives to antidepressants. D18,26
Higher doses associated with long-term SSRI use were
considered to be due to a combination of factors, greater
depression severity with more refractory symptoms and
dose escalation over the years for those prescribed SSRIs
in response to crises, as previous dose increases were
considered effective. However, the dose may not have
been reviewed and reduced at a later date, and then fur-
ther increased with subsequent crises, with colleagues
within the practice not feeling comfortable reducing
and/or stopping medication because they had not increased
the dose. As patients presented in crisis, and not when they
are well, there were challenges in ensuring proactive
routine antidepressant reviews and opportunities to appro-
priately reduce prescribing. GPs did however acknowledge
that most patients who were proactively reviewed due to
the MHRA citalopram warning were able to reduce or stop
citalopram without any significant problems.
Patient and GP fears of relapse due to reducing or
stopping antidepressants – causing more harm than good
– were also discussed by some prescribers. Especially for
patients with chronic depression, creating challenges for
restarting, optimising and stabilising individuals.
I suppose if you’ve got somebody that goes through
crisis and they’re on a drug anyway for a long time,
every time they have a crisis the dose might be
bumped up and then not reduced. So, I wonder if
there’s an element of just not reducing the drug when
it’s appropriate... and patients psychologically seem to
be quite dependent on these drugs as well. So, they
might want that increased dose too. D10,93
Higher SSRI doses associated with long-term B&Z treat-
ment were considered to be linked with patients being
more complicated, possibly having greater psychiatric
multimorbidity as well as underlying social and personal
issues not being addressed but medicated instead. Patients
were generally more willing to engage and seek pharmaco-
logical treatment and resisted reductions. However, clini-
cians rarely consider adverse effects with higher SSRI
doses increasing anxiety or B&Z’s lowering mood.
…it is probably if you’ve got somebody who’s on long-
term benzos it suggests they’re not very well. There’s
long-term issues there. …probably most of those issues
are not going to be dealt with by a drug. D24,74
Finally, in summarising the factors influencing anti-
depressant prescribing and dose used, data indicated that
‘doing the right thing’ and appropriately initiating anti-
depressants where there was a clear need increased anti-
depressant prescribing growth, Fig. 1. However, after
patients were established on antidepressants and with
increasing treatment duration, there were fewer and
fewer factors over time which provided counterbalances
to reduce prescribing and use, thus explaining the
phenomenon sustaining and driving net antidepressant
prescribing growth over time.
Discussion
Summary
Diagnosising and treating depression was rarely seen as
a simple task or process by GPs due to the complex
interaction of normal life events, relationships, social
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and environmental pressures. Treatment involved ethical
and professional imperatives expressed as two overarch-
ing concepts of ‘doing the right thing’ and achieving the
‘right care fit’ for individuals. This involved medicalised
and non-medicalised patient-centred approaches, with
antidepressants only being a single facet of individualised
care (Fig. 2).
Five factors were strongly influential: 1) Depression
diagnosis and management; 2) Patients’ expectations and
characteristics; 3) GP’s experience and relationships; 4)
Antidepressant use: safety, risk management and effective-
ness; and 5) Review frequency. The magnitude of the
influence exerted by these factors varied with the individ-
ual’s needs; treatment options; antidepressants prescribed
and doses used over time, from first presentation, to anti-
depressant initiation and longer-term treatment. Many
GPs were unaware that onset of action occurred within 1-
2 weeks, preferring to wait 8-12 weeks before increasing
or switching.
When faced with distressed patients showing symptoms
of moderate to severe depression, GPs were confident
prescribing SSRIs which they considered as safe and
effective medicines, as well as ethically and professionally
appropriate. However, individual patient comorbidities,
national safety warnings and use of sedating antidepressants
as non-addictive alternatives to B&Zs influenced drug
choice for managing risks, optimising patient safety and
benefit.
Many GPs were also unaware that higher SSRI doses
lacked greater efficacy. This lack of awareness was ac-
companied by: ongoing pressures to maintain prescrib-
ing (e.g. patient wishes, fear of depression recurrence);
few perceiving continuation as problematic (e.g. lack of
safety concerns); and the lack of proactive medication
reviews (e.g. patients only present in crisis), all combin-
ing to further drive antidepressant prescribing growth
over time (Fig. 1).
Strengths and limitations
Strengths: The main strength of this study was the sam-
pling frame used which ensured the views of a wide var-
iety of working GPs’ experiences were captured from a
large urban region with the same formulary, prescribing
support team and local depression guidelines. This study
also sought local GP perspectives on previous research
findings from other general practices within their urban
region [22], thereby allowing GPs to use their unique
insight in considering local and national contextual issues
contributing to the use of higher SSRI doses, as seen else-
where [28, 29]. Another advantage was that during the
study period there were no changes to the local formulary,
prescribing support team activities or depression guidelines,
although in May 2015 the British Association of
Psychopharmacology issued new guidelines [17]. This was
assessed as having negligible effects on GPs’ responses, as
most acknowledged guidance was a weak influencing factor
on prescribing. Finally, as GPs acknowledged that prescrib-
ing support teams did influence their prescribing, they were
asked if the interviewer (CFJ) being a prescribing support
pharmacist had influenced their responses, to which they
indicated that this had not.
Limitations: As GPs were not incentivised to participate
we suspect that participants may have been more inter-
ested in mental health and psychotropic prescribing, and
more willing to openly share experience and reflect on
practice. Some potential participants acknowledged that a
lack of time and work pressure prohibited study participa-
tion when contacted by telephone. Emergent themes were
discussed as part of the interview, however these themes
were not overtly checked for trustworthiness with future
interviewees. The variety and availability of medicalised
and non-medicalised support services did vary within the
region which may have influenced prescribing, however
GPs acknowledged that these were only one aspect of
patient care and support, and such variation in support
services will also be the case in other urban regions.
Finally, although data collected from one large urban
region may also be considered a limitation as rurality and
regional variations are associated with prescribing varia-
tions [32], the findings are of interest to others working in
similar urban practices.
Comparison and links with literature
Safety and risk management were recurring features of
this study. Other studies have highlighted that GPs were
confident using SSRIs due to perceived and actual safety
benefits when compared with other antidepressants
[38, 39]. This study highlights that national safety
warnings have changed SSRI prescribing practice,
reducing citalopram use and increasing sertraline use
which is traditionally prescribed at higher doses [21].
It also highlights prescribers’ preference for low dose
mirtazapine or trazodone instead of more risky B&Zs.
However as with B&Zs, tolerance develops to anti-
depressant sedative effects within a short period of
time [40, 41].
Experience, training and individual patient characteris-
tics influenced drug choice and use, as reported elsewhere
[42, 43], however some GPs indicated that prescribing
became more “idiosyncratic”, using learned experience
and habits to achieve the ‘best care fit’ for individuals. In
one systematic review such experience was identified as a
barrier to the use of evidence-based medicine in practice
[44]. However, in contrast to our study, they did not con-
sider the role of specialist services affecting GPs’ treatment
decisions, whether that consisted of shared experience
and good working relationships, or conversely, a lack of
robust support structures and fractured care [45]. In part,
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some of these idiosyncrasies and experiences may contrib-
ute to variations in antidepressant prescribing as one part-
ner within a practice can skew the prescribing figures [46].
Unexpectedly, prescriber preference for waiting as long
as 8 to 12 weeks before increasing or switching antidepres-
sants links with a previous quantitative study demonstrat-
ing an 8 week lag in drug optimisation [47]. Together these
identify a new potential factor which may influence early
antidepressant discontinuation, possibly linking with
perceived inertia and service dissatisfaction as previously
identified [48, 49]. Prescribers also demonstrated that anti-
depressants were only one of many treatment modalities,
and that the GPs themselves had a therapeutic function as
listener, counsellor and facilitator [49–51], as well as
creating space through use of sickness certificates [52]. As
with other studies, GPs rarely saw depression diagnosis and
management as a simple task or process. This was due to
the complex interplay of social, environmental and comor-
bidity issues, as well as individuals’ expectations of happi-
ness and unvoiced agendas [38, 53]. Although GPs did not
readily take the perceived easy option to prescribe antide-
pressants, preferring instead to ‘watch and wait’, they would
consider prescribing earlier if depressive symptoms were
more severe and/or they knew the patient well [42, 50].
Unlike other studies identifying patients’ expectations of
antidepressants being a ‘quick fix’ [38, 49], GPs in this study
were clear in viewing this as not being unique to depression
treatment, but reflecting wider societal expectations.
Implications for practice
The main implications for practitioners are to be more
aware of SSRI dose limitations; higher doses lacking
greater efficacy, and time to effect when treating depres-
sion [17, 30, 31]. This would potentially have direct and
indirect effects on reducing unnecessary prescribing and
adverse drug effects, e.g. anxiety and insomnia which
might be mistaken for residual depressive symptoms. As
well as reducing the co-prescribing of sedating antidepres-
sants, and antipsychotics or B&Zs with their respective
cardiometabolic [54] and mood lowering effects [55, 56].
Another dosing concern is the routine use of subtherapeu-
tic mirtazapine doses which may help anxiety and/or
insomnia symptoms in the short-term for individuals with
mixed depression anxiety but does not optimise depres-
sion treatment in line with current evidence [57].
An 8-12 week delaying in drug optimisation potentially
slows patient recovery, and when doses and/or drugs are
changed it might be harder to differentiate true anti-
depressant response from spontaneous remission, as 50%
of patients recover within 12 weeks [58]. Therefore, in
order appropriately optimise antidepressant use for
depression treatment it is important that prescribers are
more aware that the greatest response occurs within the
first 2 weeks of treatment [17, 31].
Finally, a major challenge is creating time to pro-
actively review patients and their antidepressants when
individuals are not in a crisis and expecting “something
to be done”. This is easier said than done, as service
pressures, demands and staffing issues limit capacity for
proactive reviews. However, where there are safety con-
cerns e.g. MHRA citalopram/escitalopram warning, or
as part of a local initiative [21], unnecessary treatment
can be reduced or stopped through proactive review.
Future research
Treatment decisions involving complex ethical and moral
processes and judgements to achieve the ‘right care fit’
and to ‘to do the right thing’ for patients which may also
be relevant to other areas of prescribing such as antibiotic
use and minimisation. Future studies should consider the
patients’ perspective and expectations about depression
treatment and management and drug limitations. The
greater use of antipsychotics, with their known detrimen-
tal metabolic effects, to treat depression and/or concomi-
tant insomnia and anxiety is also an area for concern with
significant resource implications. Therefore, future studies
should consider monitoring and assessing the short and
long-term impact of such strategies in primary care.
Conclusion
GPs strive to ‘do the right thing’ to help people. Antide-
pressants are only a single facet of depression treatment.
However, increased awareness of drug limitations, time
to effect, more rapid switching and regular proactive re-
views may help optimise care and appropriately minim-
ise antidepressant prescribing.
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